These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 32061845)
21. Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer. Hare JI; Moase EH; Allen TM J Drug Target; 2013 Jan; 21(1):87-96. PubMed ID: 23039213 [TBL] [Abstract][Full Text] [Related]
22. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461 [TBL] [Abstract][Full Text] [Related]
24. Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy. Kumar Mehata A; Bharti S; Singh P; Viswanadh MK; Kumari L; Agrawal P; Singh S; Koch B; Muthu MS Colloids Surf B Biointerfaces; 2019 Jan; 173():366-377. PubMed ID: 30316083 [TBL] [Abstract][Full Text] [Related]
25. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657 [TBL] [Abstract][Full Text] [Related]
26. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Raju A; Muthu MS; Feng SS Expert Opin Drug Deliv; 2013 Jun; 10(6):747-60. PubMed ID: 23458409 [TBL] [Abstract][Full Text] [Related]
27. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer. Naruphontjirakul P; Viravaidya-Pasuwat K Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670 [No Abstract] [Full Text] [Related]
28. In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an (125)I-labelled DNA-intercalator. Fondell A; Edwards K; Unga J; Kullberg E; Park JW; Gedda L J Drug Target; 2011 Nov; 19(9):846-55. PubMed ID: 21692679 [TBL] [Abstract][Full Text] [Related]
29. Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells. Ringhieri P; Mannucci S; Conti G; Nicolato E; Fracasso G; Marzola P; Morelli G; Accardo A Int J Nanomedicine; 2017; 12():501-514. PubMed ID: 28144135 [TBL] [Abstract][Full Text] [Related]
30. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702 [TBL] [Abstract][Full Text] [Related]
32. Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: The effect of serine-glycine repeated peptides as a spacer. Suga T; Fuchigami Y; Hagimori M; Kawakami S Int J Pharm; 2017 Apr; 521(1-2):361-364. PubMed ID: 28237886 [TBL] [Abstract][Full Text] [Related]
33. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin. Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474 [TBL] [Abstract][Full Text] [Related]
34. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes. Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192 [TBL] [Abstract][Full Text] [Related]
36. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570 [TBL] [Abstract][Full Text] [Related]
37. Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study. Kószó R; Sántha D; Büdi L; Erfán J; Győrfy K; Horváth Z; Kocsis J; Landherr L; Hitre E; Máhr K; Pajkos G; Pápai Z; Kahán Z Pathol Oncol Res; 2017 Jul; 23(3):505-511. PubMed ID: 27771885 [TBL] [Abstract][Full Text] [Related]
38. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Pivot X; Im SA; Guo M; Marmé F Breast Cancer; 2018 May; 25(3):370-374. PubMed ID: 29302858 [TBL] [Abstract][Full Text] [Related]
39. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T; Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767 [TBL] [Abstract][Full Text] [Related]
40. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]